Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: Improved sleep-time blood pressure control with bedtime dosing

Chronobiology International

Volumn 28, Issue 7, 2011, Pages 601-610

  Hermida, Ramón C ^a   Ayala, Diana E ^a   Mojón, Artemio ^a   Fontao, María J ^a   Fernández, José R ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Asleep blood pressure; Chronotherapy; Combination therapy; Dipper; Essential hypertension; Hydrochlorothiazide; Non dipper; Valsartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SLEEP; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 80052065356     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2011.589935     Document Type: Article

References (44)

1. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. (2007). Predictors of all-cause mortality in clinical ambulatory monitoring. Unique aspects of blood pressure during sleep. Hypertension 49:1235-1241. (Pubitemid 46809363)
2. Blacher J, Gasowski J, Staessen JA, Girerd X, This L, Liu L, Wang JG, Fagard R, Safar ME. (2000). Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. 160:1085-1089. (Pubitemid 30227017)
3. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegard K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA. (2007). Prognostic accuracy of day versus night ambulatory blood pressure: A cohort study. Lancet 370:1219-1229. (Pubitemid 47503300)
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ. (2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252. (Pubitemid 37553153)
5. Dezii CM. (2000). A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managed Care 9(9 Suppl):2-6.
6. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. (2005). Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin Outcome Study. Hypertension 46:156-161. (Pubitemid 40946507)
7. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, Zimmerman MB, Bergus BR. (2006). Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47:352-358. (Pubitemid 43740274)
8. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51:55-61. (Pubitemid 350307104)
9. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, KikuyaM, Björklund- Bodegard K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA. (2010). Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J. Hypertens. 28:2036-2045.
10. Fernández JR, Hermida RC. (1998). Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol. Int. 15:191-204. (Pubitemid 28189681)
11. Fernández JR, Mojón A, Hermida RC. (2004). Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol. Int. 21:467-482.
12. Hansson L, Hedner T, Dahlöf B. (1992). Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press. 1:113-119.
13. Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. (2005). Treatment of non-dipper hypertension with bedtime administration of valsartan. J. Hypertens. 23:1913-1922. (Pubitemid 41830432)
14. Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007a). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715-722. (Pubitemid 47442736)
15. Hermida RC, Ayala DE. Fernandez JR, Mojón A, Calvo C. (2007b). Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev. Esp. Cardiol. 60:131-138. (Pubitemid 46566967)
16. Hermida RC, Ayala DE, Fernández JR, Calvo C. (2008a). Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:69-76. (Pubitemid 350307106)
17. Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernández JR. (2008b). Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol. Int. 25:950-970.
18. Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61-79.
19. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2010a). Chronotherapy with valsartan/amlodipine combination in essential hypertension: Improved blood pressure control with bedtime dosing. Chronobiol. Int. 27:1287-1303.
20. Hermida RC, Ayala DE, Mojon A, Fernandez JR. (2010b). Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol. Int. 27:1629-1651.
21. Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. (2011a). Circadian rhythms: Role in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am. J. Hypertens. 24:383-391.
22. Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011b). Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. In press.
23. Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011c). Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 34;1270-1276.
24. Inaba M, Noguchi Y, Yamamoto T, Imai T, Hatano M, Yagi S, Katayama S. (2004). Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens. Res. 27:141-145. (Pubitemid 38489076)
25. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 45:240-245. (Pubitemid 40179967)
26. Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Kher Y. (2005). Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial. Clin. Ther. 27:1013-1021. (Pubitemid 41262459)
27. Mallion JM, Carretta R, Trenkwalder P, Martinez JF, Tykarski A, Teitelbaum I, Oddou P, Fagan T. (2003). Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press. 12(Suppl 1):36-43. (Pubitemid 36681971)
28. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105-1187.
29. Meng Y, Zhang Z, Liang X, Wu C, Qi G. (2010). Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. Acta Cardiol. 65:309-314.
30. Milani RV. (2005). Reaching for aggressive blood pressure goals: Role of angiotensin receptor blockade in combination therapy. Am. J. Manag. Care. 11(Suppl 7):S220-S227. (Pubitemid 41361629)
31. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. (2002). Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J. Hypertens. 20:2183-2189. (Pubitemid 35388236)
32. Palatini P. (2005). Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J. Clin. Hypertens. 7:96-101.
33. Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M. (1998). Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J. Hypertens. 16:385-393. (Pubitemid 28101767)
34. Pool JL, Glazer R,Weinberger M, Alvarado R, Huang J, Graff A. (2007). Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A doubleblind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin. Ther. 29:61-73. (Pubitemid 46414029)
35. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911-1929.
36. Raftery EB, Melville DI, Gould BA, Mann S, Whittington JR. (1981). A study of the antihypertensive action of xipadime using ambulatory intra-arterial monitoring. Br. J. Clin. Pharmacol. 12:381-385. (Pubitemid 11039909)
37. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. (2003). Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebocontrolled trials with respect to ABPM measurements. J. Hypertens. 21:1291-1298.
38. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. (2010). Administration-time-dependent effect of blood pressure-lowering medications: Basis for the chronotherapy of hypertension. Blood Press. Monit. 15:173-180.
39. Tofé S, García B. (2009). 24-Hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J. Clin. Hypertens. (Greenwhich) 11:426-431.
40. Uzu T, Kimura G. (1999). Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100:1635-1638. (Pubitemid 29477273)
41. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. (1997). Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 96:1859-1862. (Pubitemid 27400745)
42. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. (1994). Ambulatory blood pressure: An independent predictor of prognosis in essential hypertension. Hypertension 24:793-801. (Pubitemid 24363980)
43. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. (2001). Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103:2579-2584. (Pubitemid 32521968)
44. Wagstaff AJ. (2006). Valsartan/hydrochlorothiazide: A review of its use in the management of hypertension. Drugs 66:1881-1901. (Pubitemid 44596199)